Buserelin treatment of advanced prostatic carcinoma: prognostic factor analysis.

@article{Veronesi1992BuserelinTO,
  title={Buserelin treatment of advanced prostatic carcinoma: prognostic factor analysis.},
  author={Andrea Veronesi and Giovanni Lo Re and V Dal B{\`o} and S Foladore and Pedro Belmonte and B Ciaccio and Silvia Franceschi and Renato Talamini and Silvio Monfardini and M. Francini},
  journal={European urology},
  year={1992},
  volume={21 4},
  pages={274-9}
}
From August 1986 to August 1990, 116 patients with prostatic carcinoma, advanced disease (stage C-D1 only in patients older than 75 years, or D2) were treated with Buserelin (0.5 mg 3 times/day subcutaneously for 7 days, followed by 0.4 mg 3 times/day intranasally) until progression. No concomitant antiandrogens were administered. Of the 108 evaluable… CONTINUE READING